- Home
- CIK vs MCRB Comparison
CIK vs MCRB Comparison
Compare CIK & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIK
- MCRB
- Stock Information
- Founded
- CIK 1987
- MCRB 2010
- Country
- CIK United States
- MCRB United States
- Employees
- CIK N/A
- MCRB N/A
- Industry
- CIK Finance/Investors Services
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- CIK Finance
- MCRB Health Care
- Exchange
- CIK Nasdaq
- MCRB Nasdaq
- Market Cap
- CIK 159.3M
- MCRB 141.9M
- IPO Year
- CIK N/A
- MCRB 2015
- Fundamental
- Price
- CIK $2.95
- MCRB $0.80
- Analyst Decision
- CIK
- MCRB Buy
- Analyst Count
- CIK 0
- MCRB 4
- Target Price
- CIK N/A
- MCRB $5.63
- AVG Volume (30 Days)
- CIK 115.4K
- MCRB 875.0K
- Earning Date
- CIK 01-01-0001
- MCRB 03-04-2025
- Dividend Yield
- CIK 9.03%
- MCRB N/A
- EPS Growth
- CIK N/A
- MCRB N/A
- EPS
- CIK N/A
- MCRB N/A
- Revenue
- CIK N/A
- MCRB $126,325,000.00
- Revenue This Year
- CIK N/A
- MCRB N/A
- Revenue Next Year
- CIK N/A
- MCRB N/A
- P/E Ratio
- CIK N/A
- MCRB N/A
- Revenue Growth
- CIK N/A
- MCRB 12856.41
- 52 Week Low
- CIK $2.50
- MCRB $0.54
- 52 Week High
- CIK $3.19
- MCRB $1.53
- Technical
- Relative Strength Index (RSI)
- CIK 50.60
- MCRB 46.38
- Support Level
- CIK $2.92
- MCRB $0.81
- Resistance Level
- CIK $2.98
- MCRB $0.84
- Average True Range (ATR)
- CIK 0.03
- MCRB 0.04
- MACD
- CIK -0.00
- MCRB 0.00
- Stochastic Oscillator
- CIK 33.33
- MCRB 45.58
About CIK Credit Suisse Asset Management Income Fund Inc.
Credit Suisse Asset Mgmt Income Fund Inc is a closed-end management investment company. The investment objective of the fund is to provide current income consistent with the preservation of capital. Credit Suisse serves as an investment adviser for the fund. Asset Management offers a wide range of investment products and functions across asset classes and investment styles. The division manages various regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations, and individuals.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.